Brokers Offer Predictions for FBIO Q4 Earnings

Fortress Biotech, Inc. (NASDAQ:FBIO) – Investment analysts at HC Wainwright issued their Q4 2024 earnings per share (EPS) estimates for shares of Fortress Biotech in a report issued on Monday, November 18th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will earn ($0.83) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $26.00 target price on the stock. The consensus estimate for Fortress Biotech’s current full-year earnings is ($2.65) per share. HC Wainwright also issued estimates for Fortress Biotech’s FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($1.07) EPS and FY2027 earnings at ($0.46) EPS.

Separately, StockNews.com lowered shares of Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.67.

Fortress Biotech Stock Performance

FBIO stock opened at $1.59 on Wednesday. The company has a market cap of $43.88 million, a price-to-earnings ratio of -0.52 and a beta of 1.75. The business’s 50-day moving average is $1.70 and its two-hundred day moving average is $1.83. Fortress Biotech has a fifty-two week low of $1.36 and a fifty-two week high of $4.43.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in Fortress Biotech during the first quarter valued at approximately $31,000. Integrated Wealth Concepts LLC boosted its holdings in Fortress Biotech by 68.2% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 46,100 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 18,700 shares during the period. Atria Investments Inc boosted its holdings in Fortress Biotech by 58.4% in the 3rd quarter. Atria Investments Inc now owns 71,484 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 26,351 shares during the period. 180 Wealth Advisors LLC purchased a new stake in Fortress Biotech in the 2nd quarter worth $107,000. Finally, B. Riley Wealth Advisors Inc. bought a new stake in Fortress Biotech during the 2nd quarter valued at approximately $207,000. 96.51% of the stock is currently owned by institutional investors.

Insider Activity at Fortress Biotech

In related news, CEO Lindsay A. Md Rosenwald acquired 763,359 shares of the firm’s stock in a transaction dated Monday, September 23rd. The shares were purchased at an average price of $1.84 per share, with a total value of $1,404,580.56. Following the completion of the purchase, the chief executive officer now directly owns 3,657,264 shares of the company’s stock, valued at $6,729,365.76. This represents a 26.38 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 33.40% of the stock is owned by company insiders.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.